EGF receptor as a therapeutic target

Alexander Levitzki

doi:10.1016/S0169-5002(03)00134-X

EGF receptor as a therapeutic target

Alexander Levitzki^*

^*Corresponding author for this work

Alexander Silberman Institute of Life Sciences

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a role in lung cancers, with special emphasis on the way EGFR/Her-2 signaling cooperates with other signaling pathways.

Original language	English
Pages (from-to)	9-14
Number of pages	6
Journal	Lung Cancer
Volume	41
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/S0169-5002(03)00134-X
State	Published - 1 Aug 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

EGFR
Her-2
Lung cancer
Tyrphostins

Access to Document

10.1016/S0169-5002(03)00134-X

Cite this

@article{2b76d9c8d3ad4c8999b307330fb83b0e,

title = "EGF receptor as a therapeutic target",

abstract = "EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a role in lung cancers, with special emphasis on the way EGFR/Her-2 signaling cooperates with other signaling pathways.",

keywords = "EGFR, Her-2, Lung cancer, Tyrphostins",

author = "Alexander Levitzki",

year = "2003",

month = aug,

day = "1",

doi = "10.1016/S0169-5002(03)00134-X",

language = "אנגלית",

volume = "41",

pages = "9--14",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "SUPPL. 1",

}

TY - JOUR

T1 - EGF receptor as a therapeutic target

AU - Levitzki, Alexander

PY - 2003/8/1

Y1 - 2003/8/1

N2 - EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a role in lung cancers, with special emphasis on the way EGFR/Her-2 signaling cooperates with other signaling pathways.

AB - EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a role in lung cancers, with special emphasis on the way EGFR/Her-2 signaling cooperates with other signaling pathways.

KW - EGFR

KW - Her-2

KW - Lung cancer

KW - Tyrphostins

UR - https://www.scopus.com/pages/publications/0038449116

U2 - 10.1016/S0169-5002(03)00134-X

DO - 10.1016/S0169-5002(03)00134-X

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 12867057

AN - SCOPUS:0038449116

SN - 0169-5002

VL - 41

SP - 9

EP - 14

JO - Lung Cancer

JF - Lung Cancer

IS - SUPPL. 1

ER -

EGF receptor as a therapeutic target

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this